NUMD on OTC

Nu-Med Plus, Inc.

American surgical and medical instruments and apparatus company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

TickerNUMD on OTC¹
IndustrySurgical & Medical Instruments & Apparatus¹
HeadquartersPort Jefferson, New York¹
Incorporated inUT²
Business address640 Belle Terre Rd. 2 E, Port Jefferson, Ny 11777²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

FDA approval prior to initiating sales in the United States and the approval of similar international agencies in their respective countries.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-429.5%Return on equity⁴

Financial statements

Revenue⁵$0 in 2020

Operating income⁵⁶-$2.0M in 2020+96% since 2019

Net income⁵⁶-$2.0M in 2020+94% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31
General and administrative expense	$23.1K	$34.3K
Rent expense	$58	$300
Professional and consulting fees	$25.8K	$28.7K
Total operating expenses	$49.0K	$63.3K
Operating loss	-$49.0K	-$63.3K
Interest expense	-$7.2K	-$5.0K
Total other income (expense)	-$7.2K	-$5.0K
Loss before income taxes	-$56.2K	-$68.3K
Net loss	-$56.2K	-$68.3K
Basic earnings per share	$0.00	$0.00
Diluted earnings per share	$0.00	$0.00
Weighted average common shares outstanding - basic (in Shares)	83.5M shares	83.5M shares
Weighted average common shares outstanding - diluted (in Shares)	83.5M shares	83.5M shares

Total assets⁵⁶$557.1K in 2020+1117% since 2019

Total liabilities⁵⁶$89.4K in 2020−79% since 2019

Shareholders’ equity⁵⁴$467.7K in 2020

Cash⁶$188.5K in 2020+2563% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$661	$2.4K
Prepaid expense	$7.2K	$7.0K
Total current assets	$7.9K	$9.4K
Total assets	$7.9K	$9.4K
Accounts payable	$48.2K	$43.0K
Convertible note payable	$100.0K	$100.0K
Notes payable related party	$112.5K
Accrued expense	$18.0K	$14.7K
Total current liabilities	$279.2K	$224.5K
Total liabilities	$279.2K	$224.5K
Common stock; $0.001 par value per share; 90,000,000 authorized; 83,548,469 and 83,548,469 shares issued and outstanding, as of December 31, 2025 and 2024, respectively.	$83.5K	$83.5K
Additional paid-in capital	$9.6M	$9.6M
Accumulated deficit	-$9.9M	-$9.9M
Total stockholders' deficit	-$271.3K	-$215.1K	-$146.8K
Total liabilities and stockholders' deficit	$7.9K	$9.4K
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in Shares)	0 shares	0 shares
Preferred stock, shares outstanding (in Shares)	0 shares	0 shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	90.0M shares	90.0M shares
Common stock, shares issued (in Shares)	83.5M shares	83.5M shares
Common stock, shares outstanding (in Shares)	83.5M shares	83.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$661	$2.4K
Prepaid expense	$7.2K	$7.0K
Total current assets	$7.9K	$9.4K
Total assets	$7.9K	$9.4K
Accounts payable	$48.2K	$43.0K
Convertible note payable	$100.0K	$100.0K
Notes payable related party	$112.5K
Accrued expense	$18.0K	$14.7K
Total current liabilities	$279.2K	$224.5K
Total liabilities	$279.2K	$224.5K
Common stock; $0.001 par value per share; 90,000,000 authorized; 83,548,469 and 83,548,469 shares issued and outstanding, as of December 31, 2025 and 2024, respectively.	$83.5K	$83.5K
Additional paid-in capital	$9.6M	$9.6M
Accumulated deficit	-$9.9M	-$9.9M
Total stockholders' deficit	-$271.3K	-$215.1K	-$146.8K
Total liabilities and stockholders' deficit	$7.9K	$9.4K
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in Shares)	0 shares	0 shares
Preferred stock, shares outstanding (in Shares)	0 shares	0 shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	90.0M shares	90.0M shares
Common stock, shares issued (in Shares)	83.5M shares	83.5M shares
Common stock, shares outstanding (in Shares)	83.5M shares	83.5M shares

Cash from operations⁵⁶-$414.8K in 2020−27% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31
Net income (loss)	-$56.2K	-$68.3K
Prepaid expenses	-$250	-$350
Accounts payable	$5.2K	$35.0K
Related party payables		$20.6K
Accrued expense	$3.3K	$8.7K
Net cash used in operating activities	-$48.0K	-$4.4K
Note payable related party	$46.3K
Net cash provided by financing activities	$46.3K
Net change in cash	-$1.7K	-$4.4K
Notes payable related party accounts payable converted to note	$66.2K

Compare Nu-Med Plus, Inc. with another company

Leadership

Who has led Nu-Med Plus, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

Keith L. Merrell2023

201520202025

Chief executive officerWilliam C. Hayde Nov 22, 2022 to Dec 12, 2023¹¹
Chief executive officerJeffrey Lynn Robins Feb 11, 2013 to Feb 11, 2013¹²
Chief financial officerKeith L. Merrell Dec 12, 2023 to Dec 12, 2023¹³

Board members and other officers (13)

SVP and Chief GeologistFred Tejada Aug 25, 2026 to now¹⁴
VP of Medical MarketingBrett J. Earl Feb 9, 2015 to Apr 24, 2015¹⁵
VP of Scientific AdvancementThomas A. Tait Feb 9, 2015 to Feb 9, 2015¹⁶
Vice President of OperationsWilliam G. Moon Feb 11, 2013 to Feb 11, 2013¹⁷
Vice President of TechnologyCraig Morrison Feb 12, 2013 to Aug 9, 2016¹⁸
Board memberFred Tejada Aug 25, 2026 to now¹⁴
Board memberKeith L. Merrell Dec 12, 2023 to Dec 12, 2023¹³
Board memberWilliam C. Hayde Nov 22, 2022 to Dec 12, 2023¹¹
Board memberBrett J. Earl Feb 9, 2015 to Apr 24, 2015¹⁵
Board memberThomas A. Tait Feb 9, 2015 to Feb 9, 2015¹⁶
Board memberJeffrey Lynn Robins Feb 11, 2013 to Dec 12, 2023¹²
Board memberWilliam G. Moon Feb 11, 2013 to Feb 11, 2013¹⁷
Board memberCraig Morrison Feb 12, 2013 to Aug 9, 2016¹⁸

Timeline

Nov 22, 2022New chief executive William C. Hayde becomes CEO¹¹
Feb 11, 2013New chief executive Jeffrey Lynn Robins becomes CEO¹²

Filings

45 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 13 major events, 6 insider forms, 1 large holders, 3 other. The latest 20:

Aug 25, 2026SCHEDULE 13D EDGAR
Aug 25, 20264 EDGAR
Aug 25, 20263 EDGAR
Aug 25, 20268-K EDGAR
Aug 14, 202610-Q EDGAR
Jul 10, 20268-K EDGAR
Jun 30, 20268-K EDGAR
May 14, 202610-Q EDGAR
Apr 15, 202610-K ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2025 EDGAR
Mar 31, 2026NT 10-K REQUEST FOR AN EXTENSION OF TIME TO FILE OUR ANNUAL REPORT ON FORM 10K FOR THE Y EDGAR
Nov 14, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025 EDGAR
Aug 11, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2025 EDGAR
May 22, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 2025 EDGAR
Mar 31, 202510-K ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2024 EDGAR
Nov 14, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 EDGAR
Oct 30, 20248-K CURRENT REPORT ON FORM 8-K DATED OCTOBER 28, 2024 EDGAR
Aug 21, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2024 EDGAR
Aug 14, 2024NT 10-Q REQUEST FOR AN EXTENSION OF TIME TO FILE OUR QUARTERLY REPORT ON FORM 10Q FOR TH EDGAR
May 15, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 2024 EDGAR
May 2, 20248-K CURRENT REPORT ON FORM 8-K DATED APRIL 28, 2024 EDGAR

The 45 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Fred TejadaSCHEDULE 13D, 1 filing Aug 25, 2026¹⁹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNu-Med Plus, Inc. filings on SEC EDGAR
2
SEC EDGARNu-Med Plus, Inc. filings on SEC EDGAR
3
SEC EDGARNu-Med Plus, Inc. annual report, Item 1 (Business)
4
SEC EDGARNu-Med Plus, Inc. 10-K for fiscal 2020
5
SEC EDGARNu-Med Plus, Inc. 10-K for fiscal 2019
6
SEC EDGARNu-Med Plus, Inc. 10-K for fiscal 2020
7
SEC EDGARNu-Med Plus, Inc. 10-Q for fiscal 2025
8
SEC EDGARNu-Med Plus, Inc. 10-Q for fiscal 2026
9
SEC EDGARNu-Med Plus, Inc. 10-K filed 2026-04-15: income statement
10
SEC EDGARNu-Med Plus, Inc. 10-K for fiscal 2019
11
SEC EDGARWilliam C. Hayde, Chief executive officer
12
SEC EDGARJeffrey Lynn Robins, Chief executive officer
13
SEC EDGARKeith L. Merrell, Chief financial officer
14
SEC EDGARFred Tejada, SVP and Chief Geologist
15
SEC EDGARBrett J. Earl, VP of Medical Marketing
16
SEC EDGARThomas A. Tait, VP of Scientific Advancement
17
SEC EDGARWilliam G. Moon, Vice President of Operations
18
SEC EDGARCraig Morrison, Vice President of Technology
19
SEC EDGARFred Tejada SCHEDULE 13D on Nu-Med Plus, Inc.